CN110974716A - 一种预防和治疗妊娠纹的组合物 - Google Patents
一种预防和治疗妊娠纹的组合物 Download PDFInfo
- Publication number
- CN110974716A CN110974716A CN201911408422.1A CN201911408422A CN110974716A CN 110974716 A CN110974716 A CN 110974716A CN 201911408422 A CN201911408422 A CN 201911408422A CN 110974716 A CN110974716 A CN 110974716A
- Authority
- CN
- China
- Prior art keywords
- composition
- ectoine
- preventing
- silanol
- striae gravidarum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 206010040925 Skin striae Diseases 0.000 title claims abstract description 47
- -1 acetyl chitosamine Chemical compound 0.000 claims abstract description 35
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims abstract description 32
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 claims abstract description 29
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 17
- 229930195725 Mannitol Natural products 0.000 claims abstract description 17
- 239000000594 mannitol Substances 0.000 claims abstract description 17
- 235000010355 mannitol Nutrition 0.000 claims abstract description 17
- 208000031439 Striae Distensae Diseases 0.000 claims abstract description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims abstract description 7
- 239000000686 essence Substances 0.000 claims abstract description 4
- 239000000499 gel Substances 0.000 claims abstract description 4
- 235000013336 milk Nutrition 0.000 claims abstract description 4
- 239000008267 milk Substances 0.000 claims abstract description 4
- 210000004080 milk Anatomy 0.000 claims abstract description 4
- 210000004303 peritoneum Anatomy 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 150000004283 biguanides Chemical class 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940057950 sodium laureth sulfate Drugs 0.000 claims 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 150000002148 esters Chemical class 0.000 abstract description 16
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 3
- 230000000699 topical effect Effects 0.000 abstract description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 32
- 239000000839 emulsion Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- 238000005303 weighing Methods 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 14
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229940075529 glyceryl stearate Drugs 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 5
- CKXRAWYXQIIMBZ-UHFFFAOYSA-N 3-methylnonane-1,2,3-triol Chemical compound CCCCCCC(C)(O)C(O)CO CKXRAWYXQIIMBZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 229940119170 jojoba wax Drugs 0.000 description 4
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002834 transmittance Methods 0.000 description 4
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 4
- 244000144725 Amygdalus communis Species 0.000 description 3
- 235000011437 Amygdalus communis Nutrition 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000008168 almond oil Substances 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- GYDYJUYZBRGMCC-INIZCTEOSA-N (2s)-2-amino-6-(dodecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCC(=O)NCCCC[C@H](N)C(O)=O GYDYJUYZBRGMCC-INIZCTEOSA-N 0.000 description 2
- XTJKNGLLPGBHHO-HNNXBMFYSA-N (2s)-5-(diaminomethylideneamino)-2-(dodecanoylamino)pentanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCCN=C(N)N XTJKNGLLPGBHHO-HNNXBMFYSA-N 0.000 description 2
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010043275 Teratogenicity Diseases 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000008309 hydrophilic cream Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 231100000378 teratogenic Toxicity 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- 231100000211 teratogenicity Toxicity 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 240000003173 Drymaria cordata Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- OAPHLAAOJMTMLY-GQCTYLIASA-N Ethyl 2-methylbut-2-enoate Chemical compound CCOC(=O)C(\C)=C\C OAPHLAAOJMTMLY-GQCTYLIASA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000038561 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- CEEMRWKKNNEQDT-UHFFFAOYSA-N Rosmanol Natural products CC(C)c1cc2C(OC(=O)C)C3OC(=O)C4(CCCC(C)(C)C34)c2c(OC(=O)C)c1OC(=O)C CEEMRWKKNNEQDT-UHFFFAOYSA-N 0.000 description 1
- 241000221095 Simmondsia Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 244000284012 Vetiveria zizanioides Species 0.000 description 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- OPVLOHUACNWTQT-UHFFFAOYSA-N azane;2-dodecoxyethyl hydrogen sulfate Chemical compound N.CCCCCCCCCCCCOCCOS(O)(=O)=O OPVLOHUACNWTQT-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940062933 dimethylsilanol hyaluronate Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- OJLOUXPPKZRTHK-UHFFFAOYSA-N dodecan-1-ol;sodium Chemical compound [Na].CCCCCCCCCCCCO OJLOUXPPKZRTHK-UHFFFAOYSA-N 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000001696 ethyl (E)-2-methylbut-2-enoate Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 108010058058 hexapeptide-95 Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 210000001139 rectus abdominis Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- LCAZOMIGFDQMNC-FORWCCJISA-N rosmanol Chemical compound C1CCC(C)(C)[C@@H]2[C@H]3[C@@H](O)C(C=C(C(=C4O)O)C(C)C)=C4[C@]21C(=O)O3 LCAZOMIGFDQMNC-FORWCCJISA-N 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 150000004819 silanols Chemical class 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
本发明提供了一种预防和治疗妊娠纹的组合物,包括以下原料:甘露糖醛酯硅烷醇和透皮成分,所述透皮成分为乙酰壳糖胺和依克多因。所述甘露糖醛酯硅烷醇与透皮成分的质量比为(4‑40):(2‑51)。所述乙酰壳糖胺用量和依克多因用量的质量比为(3‑5):(1‑3)。该组合物为局部用组合物,可制备成水、乳、霜、精华、凝胶、腹膜等形式。本发明提供的预防和治疗妊娠纹组合物,乙酰壳糖胺和依克多因可以有效提高甘露糖醛酯硅烷醇的透皮吸收率,通过组合物产生协同增效的作用,全方位预防和改善妊娠纹,同时对人体无刺激,安全无毒副作用。本发明的组合物成分类型简单、易于制备,易与其他成分混配到化妆品中。
Description
技术领域
本发明属于化妆品领域,涉及一种预防和治疗妊娠纹的组合物。
背景技术
妊娠纹是萎缩纹的一种。萎缩纹是人体在怀孕、健身、体重骤增过程当中产生的皮肤纤维断裂现象,呈红色、白色或紫色条纹。它还包括肥胖纹、运动裂纹。运动幅度较大的身体部位,除腹部外,还有股内外侧、膝盖、臀部、腰骶等部位。正常情况下,皮肤弹性纤维与腹直肌保持一定的弹力,并在一定限度内自由伸缩。当女性怀孕超过3个月时,增大的子宫突出于盆腔,向腹腔发展,腹部开始膨隆,皮肤弹性纤维与腹部肌肉开始伸长。妊娠6个月后更加明显,这时皮肤弹性纤维逐渐出现断裂,腹部皮肤表面慢慢出现粉红色或紫红色的不规则纵形裂纹。生产后,断裂的弹性纤维逐渐得以修复,但难以恢复到以前的状态。而原先皮肤上的裂纹便渐渐褪色,最后变成银白色的妊娠纹。由于妊娠纹存在的普遍性和永久性,其破坏了女性的美观,进而影响其情绪,给患者带来了很大的精神压力,影响了其生活质量。因此,一直以来妊娠纹受到人们的广泛关注。妊娠纹也始终是医学界研究的热点,其治疗方法也在不断地探索中。
国内外关于妊娠纹的预防和治疗产品很多,主要包括维A酸、各种植物油或提取物等。维A酸是常用的外用治疗产品之一,通过作用于成纤维细胞,刺激皮肤外基质蛋白的合成,从而形成新的结缔组织带,并可提高用药部位的张力强度,但维A酸较严重的不良反应限制了其应用,维A酸对皮肤具有较强的刺激,会引起皮肤出现红斑、脱屑,长期应用会导致全身吸收可能引起肝损害,而且其具有潜在的的胚胎毒性和致畸性,孕妇在妊娠早期禁用。
申请号为201610137465.0的专利公开了一种消除妊娠纹的植物提取组合物,该组合物由山茶籽提取物15-30、岩兰草提取物10-20、霍霍巴籽提取物10-15,积雪草提取物5-10、橄榄提取物8-15、酵素粉5-8、植物乳杆菌菌粉2-5组成,该组合物效果明显,但是存在组分多、用量多、制备繁琐的缺点。
申请号为201610875293.7的专利公开了一种含山茶油的收腹去妊娠纹组合物,该组合物包括:D-柠檬烯0.1%-0.5%、芳樟醇0.03%-0.08%、左旋薄荷醇0.03%-0.05%、惕各酸乙酯0.01%-0.03%、香荆芥酚0.01%-0.03%、迷迭香酚0.03%-0.08%和山茶油99.23%-99.79%,该组合物用量少,但是组分较复杂,而且组分均为油溶性成分,很难直接加到水剂,限制了其在化妆品配方中应用。
申请号为201410824539.9的专利公开了一种去妊娠纹水包油霜及其制备方法,该去妊娠纹水包油霜虽然安全无毒副作用,但是效果不明显。
由此可看出,现有的产品在预防和治疗妊娠纹时存在效果不明显、成分多或者对人体有潜在危害等不足。因此亟需开发一种疗效明确、组分简单且无害的产品。
发明内容
针对目前预防和治疗妊娠纹产品疗效差、安全性差的问题,本发明提供一种包含甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因的预防和治疗妊娠纹的组合物,成分简单、易于制备,与其他成分混性好,且安全无毒。
为实现上述目的,本发明采用如下技术方案。
一种预防和治疗妊娠纹的组合物,包括以下原料:甘露糖醛酯硅烷醇和透皮成分,所述透皮成分为乙酰壳糖胺和依克多因。
所述甘露糖醛酯硅烷醇与透皮成分的质量比为(4-40):(2-51);优选为4:3。所述乙酰壳糖胺用量和依克多因用量的质量比为(3-5):(1-3),优选为4:2。
优选的,所述组合物包括以下重量百分含量的原料:甘露糖醛酯硅烷醇0.01%-1.0%、乙酰壳糖胺0.01%-0.5%、依克多因0.01%-0.5%。
所述组合物,还可以包括其他预防和治疗妊娠纹的有效成分,如植物提取物、维生素及其衍生物、蛋白质、肽类和氨基酸中的一种或多种。
所述的一种预防和治疗妊娠纹组合物还可以包括其他辅料,如保湿剂、防腐剂、酸碱调节剂、表面活性剂、黏度调节剂、香料和色素中的一种或几种。所述保湿剂选自但不限于丙三醇、山梨醇、甜菜碱、尿囊素、β-葡聚糖和聚谷氨酸钠中的一种或多种。所述防腐剂选自但不限于戊二醇、丁二醇、苯氧乙醇、三氯叔丁醇、对羟基苯乙酮、季铵盐类、双胍类中的一种或多种。所述酸碱调节剂选自但不限于柠檬酸、氢氧化钠、三乙醇胺和氨甲基丙醇中的一种或多种。所述表面活性剂选自但不限于AES铵盐、K12铵盐、月桂醇醚硫酸铵、月桂醇硫酸钠、椰油酰胺丙基甜菜碱中的一种或多种。所述的黏度调节剂选自但不限于氯化钠、氯化铵、椰油酰胺甜菜碱类、汉生胶、丙烯酸酯类中的一种或多种。
优选的,上述组合物含有保湿剂。
一种含有上述预防和治疗妊娠纹组合物的化妆品。所述化妆品包括但不限于水、乳、霜、精华、凝胶、腹膜。
本发明具有以下优点:
本发明提供的预防和治疗妊娠纹组合物,含有甘露糖醛酯硅烷醇、乙酰壳糖胺和依克多因,比仅仅使用甘露糖醛酯硅烷醇具有更加明显的效果,乙酰壳糖胺和依克多因可以有效提高甘露糖醛酯硅烷醇的透皮吸收率,通过组合物产生协同增效的作用,全方位预防和改善妊娠纹,同时对人体无刺激,安全无毒副作用。该组合物为局部用组合物,可制备成水、乳、霜、精华、凝胶、腹膜等形式。所述组合物用量少效果明显,且对人体安全、无毒副作用。同时,本发明的组合物成分类型简单、易于制备,易与其他成分混配到化妆品中。
具体实施方式
下面结合实施例对本发明做进一步说明,但本发明不受下述实施例的限制。
实施例1 透皮成分对甘露糖醛酯硅烷醇透皮吸收率影响
1. 组合物溶液制备
按照表1的配方称取不同组分,搅拌混匀后得到组合物,然后加水至甘露糖醛酯硅烷醇在溶液中的浓度为0.04%。
表1 不同用量的甘露糖醛酯硅烷醇和透皮成分
2. 透皮吸收率
用8% Na2S溶液除去昆明鼠背部的毛发,用蒸馏水将皮肤表面清洗干净,24h后观察皮肤没有损伤后脱颈处死小鼠,取下小鼠背部的皮肤,除去皮下组织与脂肪,将皮肤置于生理盐水中,4℃保存备用。
采用Franz扩散池(扩散面积1.0cm2,接受池容积为8.5cm3)进行体外透皮试验,将离体的昆明鼠皮肤固定于扩散池中,在接收池中加生理盐水10mL。将编号1-10混合物的水溶液分别置于离体鼠皮角质层一侧,水浴温度为(32.0±0.5)℃,150rpm恒速搅拌。在设定的时间点1、2、4、6、8、12h取出0.4mL接收液,同时补加等量等温生理盐水。样品过0.22μm膜滤,HPLC法测定甘露糖醛酯硅烷醇的浓度,按照公式(1)计算单位面积累积透过量Qn(mg/cm2),按照公式(2)计算累积透过率P(%):
其中,
Qn是单位面积累积透过量,mg/cm2;
cn是第n次测到药物浓度,mg/mL;
V0是接收液的体积,mL;
ci是第n次前每次测到的药物浓度,mg/mL;
Vi是样品体积,mL;
A有效扩散面积,cm2;
Qn是单位面积累积透过量,mg/cm2;
A是有效扩散面积,cm2;
c是加入药液的浓度,mg/mL;
V是加入药液的体积,mL。
表2 甘露糖醛酯硅烷醇的累积渗透量及累积透过率
由上表中的样1、样2、样3、样4的结果可知,配方中单独使用乙酰壳糖胺和依克多因均可增加甘露糖醛酯硅烷醇在皮肤的透皮速率,单独使用乙酰壳糖胺和依克多因甘露糖醛酯硅烷醇12h的累积透过百分率由13.0%分别提高到19.6%和15.1%。乙酰壳糖胺和依克多因联合应用时大大提高了甘露糖醛酯硅烷醇在皮肤的透皮速率。当乙酰壳糖胺用量和依克多因的质量比为5:1、3:1、1:1、5:3时甘露糖醛酯硅烷醇12h的累积透过率可达到59%左右,但乙酰壳糖胺用量和依克多因的质量比为4:2时甘露糖醛酯硅烷醇12h的累积透过率可达到70.9%。
实施例2 组合物的安全性评价
1. 致畸风险评估
按照2:1:1的质量比称取甘露糖醛酯硅烷醇、乙酰壳糖胺和依克多因混合均匀配制组合物。
选择一批发育良好的初成年雄鼠和雌鼠,同笼交配。当雌鼠阴道口有阴栓为受孕0天。然后选择24只受孕鼠,分为两组:空白组12只,正常饮食;试验组12只,从孕期第6天到第19天,试验组每天称量雌鼠体重,并按照0.01g/100g体重的剂量,将组合物溶于1mL水中,对小鼠进行灌胃。孕期第30天,将两组雌鼠处死,取出子宫,检查胎鼠。
表3 致畸风险评估试验结果
由表3数据可知,本发明的组合物没有致畸风险,安全性高。
2. 刺激性评估
按照2:1:1的质量比称取甘露糖醛酯硅烷醇、乙酰壳糖胺和依克多因混合均匀配制组合物。将2g、4g、8g组合物分别与98g、96g、92g乳液基质(成分:辛酸/癸酸甘油三酯7%,甘油硬脂酸酯0.5%,PEG-100甘油硬脂酸酯0.5%,甘油5%,丁二醇3%,蒸馏水84%)混合成供试乳液样品1-3。
选择30位25-50岁成年健康的女性志愿者,分为三组,每组10人。清洁其前臂曲侧,将1-3号乳液0.025g的斑试器和一个乳液基质0.025g的斑试器(空白)用低致敏胶带贴敷于受试者的左前臂曲侧,用手指轻压使之均匀涂敷于皮肤上,持续48h。去除斑试器后30min(待压痕消失后),观察皮肤反应。皮肤反应分级标准见表4,结果见表5。
表4 皮肤反应分级标准
表5 刺激性试验结果
由表5数据可知,本发明的组合物在正常使用量、2倍量和4倍量时,对皮肤均无刺激性,安全性高。
实施例3 含组合物的化妆品的制备
1. 乳液
按照表6中的组成称取甘露糖醛酯硅烷醇、乙酰壳糖胺和依克多因混合均匀配制成组合物11-15。
表6 组合物配方1
按照以下方法获得乳液:
A相:辛酸/癸酸甘油三酯7%、甜杏仁油3%、霍霍巴油1%、C14-22醇1.5%、C12-20烷基葡糖苷0.5%、甘油硬脂酸酯0.5%,PEG-100甘油硬脂酸酯0.5%;
B相:甘油5%、丁二醇3%、甲基己基甘油0.1%、加入表中比例的甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因,余量的水;
C相:苯氧乙醇0.5%。
(1)称取辛酸/癸酸甘油三酯7g、甜杏仁油3g、霍霍巴油1g、C14-22醇1.5g、C12-20烷基葡糖苷0.5g、甘油硬脂酸酯0.5g,PEG-100甘油硬脂酸酯0.5g,加热至80℃,搅拌均匀,保温15min,获得油相,备用;
(2)称取甘油5g、丁二醇3g、甲基己基甘油0.1g、加入组合物,补水至86.0g,加热至80℃,搅拌均匀,保温20min,获得水相,备用;
(3)开启均质机,向水相中缓慢加入油相,高速均质2min。
(4)冷却至35℃后,将C相加入(AB)相均质,即得乳液。
2. 膏霜
按照以下质量百分比称取原料:
A相:辛酸/癸酸甘油三酯5%、牛油果树果脂2.0%、乳木果油2.0%、霍霍巴油1%、C14-22醇1.5%、C12-20烷基葡糖苷0.5%、甘油硬脂酸酯0.5%,PEG-100甘油硬脂酸酯0.5%、生育酚 0.5%;
B相:甘油5%、黄原胶0.3%、丙烯酰二甲基牛磺酸胺/VP共聚物0.5%、丁二醇3%、甲基己基甘油0.1%、甘露糖醛酯硅烷醇0.5%、乙酰壳糖胺0.25%、依克多因0.25%,余量的水;
C相:苯氧乙醇0.5%。
按照以下方法制备膏霜:
(1)油相处理:准确称取A相成分,加热至80℃,搅拌均匀,保温15min,备用;
(2)水相处理:准确称取B相成分,加热至80℃,搅拌均匀,保温20min;
(3)乳化:开启均质,向水相中缓慢加入油相,均质2min;
(4)冷却至35℃后,将C相加入(AB)相均质,即得膏霜。
3. 凝胶
按照以下质量百分比称取原料:
甘油2.0%、丁二醇5.0%、戊二醇3.0%、羟乙基纤维素(黏度30000 mpa.s) 1.8%、甘露糖醛酯硅烷醇0.5%、乙酰壳糖胺0.25%、依克多因0.25%、棕榈酰三肽-5 0.1%,氢氧化钠适量,余量为水。
按照以下方法制备凝胶:
称取处方量的甘油、丁二醇、戊二醇、羟乙基纤维素搅拌分散均匀,加入余量的水,加热至60-80℃,搅拌溶解。待完全溶解后,降温至30-40℃,加入处方量的甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因、棕榈酰三肽-5,搅拌溶解,溶解完全后,用适量的氢氧化钠调节pH至5.5-7.5之间,即得凝胶。
对比例1
参照公布号为CN 110151595 A专利配方中的原料和制备方法制备9号乳液:
A相:辛酸/癸酸甘油三酯7%、甜杏仁油3%、霍霍巴油1%、C14-22醇1.5%、C12-20烷基葡糖苷0.5%、甘油硬脂酸酯0.5%,PEG-100甘油硬脂酸酯0.5%;
B相:甘油5%、丁二醇3%、小分子透明质酸钠0.2%、硫酸软骨素0.3%、透明质酸钠0.1%、抗坏血酸磷酸酯镁0.5%、苯氧乙醇0.5%、甲基己基甘油0.1%、蒸馏水66.19%;
C相:六肽-9 5ppm、棕榈酰三肽-1 1ppm、棕榈酰六肽-12 20ppm、甘氨酸1.47%、脯氨酸0.88%、丙氨酸0.58%、二棕榈酰基羟基脯氨酸3.39%、乙酰谷氨酸0.82%、月桂酰精氨酸1.08%、天冬氨酸0.36%、丝氨酸0.23%、月桂酰赖氨酸0.53%、缬氨酸0.17%、亮氨酸0.19%、苏氨酸0.13%、苯丙氨酸0.12%、异亮氨酸0.08%、二甲基甲硅烷醇透明质酸酯0.05%、芦丁0.05%,白雪茶提取物0.01%。
按照以下步骤制作:
(1)油相处理:准确称取A相成分,加热至80℃,搅拌均匀,保温15min,备用。
(2)水相处理:准确称取抗坏血酸磷酸酯镁,加入适量的蒸馏水,常温搅拌溶解,备用。准确称取除抗坏血酸磷酸酯镁、苯氧乙醇的其他B相成分,加热至80℃,搅拌均匀,保温20min。
(3)乳化:将抗坏血酸硫酸酯镁溶液和苯氧乙醇加入水相,80℃搅拌均匀,保温1min。开启均质,缓慢加入油相,均质2min。
(4)降温:均质后,在缓慢搅拌下降温,降至45℃,加入C相,搅拌均匀,降至35℃,停止搅拌。
对比例2
按照表7中的组成称取甘露糖醛酯硅烷醇、乙酰壳糖胺和依克多因混合均匀配制成组合物16-19。按照实施例2中乳液的制备方法和辅料比例制备乳液。
表7 组合物配方2
实施例4 产品效果
1. 皮肤弹性、保湿性测试
受试群体为平均年龄为30-50岁健康女性100名,分别使用实施例3中对应乳液编号为4、5、6、7、8,对比例1和对比例2中对应乳液编号为9-13的乳液。将受试者平均分为10组,每组使用不同的乳液,受试者在面部涂抹各试验乳液,每天早晚涂抹产品两次,试验效果进行自我对比。试验期间,受试者在试验部位不能涂抹任何其它化妆品。受试者在连续使用试验乳液的0周、2周、4周、8周后,测试皮肤水分含量、皮肤水分散失及皮肤的弹性,测试部位为颧部,测量时探头在同一受测区域重复测量3次,取平均值。
测试仪器:Cotometer MPA580的主机(德国Courage+Khazaka公司),配备皮肤水分含量Cornemeter CM825测试探头,皮肤水分散失Tewameter TM300测试探头,皮肤弹性PVM600测试探头。
计算方法:面部皮肤含水量的初始值为L0i(i=1,2….10),8周后,试验组标记为L8i(i=1,2….10),分别将L8i/L0i会得到10名志愿者的面部水分相对值,然后取平均数得到最后的皮肤含水量平均相对值。同样方法,依次得到经皮水分流失、皮肤弹性的相对数据。具体结果见表8。
表8 皮肤弹性、保湿性测试结果
由试验结果可知:甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因均可增加皮肤水分和弹性,其中单一的乙酰壳糖胺和依克多因在增加皮肤水分优于甘露糖醛酯硅烷醇,其中单一的甘露糖醛酯硅烷醇、乙酰壳糖胺在增加皮肤弹性上优于依克多因。在增加皮肤水分和弹性上组合物效果优于单一组分。因此可证明此组合物在增加皮肤水分和弹性上能够产生协同增效的效果,且效果略优于对比例1。
2. 成纤维细胞增殖试验
表9 组合物配方3
溶液1-5的配制:称取表9中编号为20-24配方量的甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因,加水至100g,搅拌溶解,即得溶液1-5。
溶液6的配制:参照公布号为CN 110151595 A专利配方中的原料来制备溶液6。
称取小分子透明质酸钠0.2g、硫酸软骨素0.3g、透明质酸钠0.1g、抗坏血酸磷酸酯镁0.5g、六肽-9 5ppm、棕榈酰三肽-1 1ppm、棕榈酰六肽-12 20ppm、甘氨酸1.47g、脯氨酸0.88g、丙氨酸0.58g、二棕榈酰基羟基脯氨酸3.39g、乙酰谷氨酸0.82g、月桂酰精氨酸1.08g、天冬氨酸0.36g、丝氨酸0.23g、月桂酰赖氨酸0.53g、缬氨酸0.17g、亮氨酸0.19g、苏氨酸0.13g、苯丙氨酸0.12g、异亮氨酸0.08g、二甲基甲硅烷醇透明质酸酯0.05g、芦丁0.05g,白雪茶提取物0.01g,加水至100g,搅拌溶解,即得溶液6。
材料与仪器:人皮肤成纤维细胞、DMEM培养基、胎牛血清、二甲基亚砜、噻唑蓝、PBS缓冲液,溶液1-6、全自动酶标仪、紫外分光光度计;
培养方法:人皮肤成纤维细胞加入DMEM培养基,置于CO2培养箱(5%CO2,湿度为95%,恒温37℃)中培养,培养48h后更换培养液,待细胞长满培养液,取出弃去培养液,加入消化液约3mL,以铺满瓶底为限,约2-3min后,当发现细胞质回缩,细胞间隙增大后,加入DMEM培养基终止反应,并制备成单细胞悬液,5000个/mL浓度接种于96孔板,每孔加入0.1mL,置于CO2培养箱(5%CO2,湿度为95%,恒温37℃)中培养,待细胞附着后,更换100mL培养液,同时分别添加溶液1-6 100mL,对照组加入相同体积的PBS缓冲液,继续培养细胞至48h,以仅添加培养液的孔为空白对照,以仅添加细胞悬液的为阴性对照,每处理5个复孔,采用MTT法测定吸光度值,并按照下面的公式计算细胞相对增殖率:
表10 成纤维细胞增殖效果试验结果
由试验结果可知:甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因均可以促进成纤维细胞增殖,组合物效果优于单一组分。因此可证明此组合物在促进进成纤维细胞增殖上能够产生协同增效的效果,且效果略优于对比例1。
3. 对胶原蛋白生成影响
实施例3,对比例1-2中的4-13号乳液,每个组5只裸鼠,在裸鼠左侧耳背上进行试验,每日早晚各涂抹一次,每次用药约1g,右侧为对照组。用药30天后将裸鼠处死,取其用药部位及对侧相应皮肤部位进行处理。采用分光光度法测定羟脯氨酸的含量,按胶原蛋白中含14%羟脯氨酸换算小鼠皮肤中胶原蛋白含量,结果见表11。
表11 促进胶原蛋白生成试验结果
由试验结果可知:甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因均可以促进胶原蛋白的合成,其中甘露糖醛酯硅烷醇、乙酰壳糖胺优于依克多因。在促进胶原蛋白合成上组合物效果优于单一组分。因此可证明此组合物在促进胶原蛋白合成上能够产生协同增效的效果,且效果和对比例1相当。
4. 预防妊娠纹功效测试
5号乳液、9号乳液,招募20名志愿者,以受试者腹部中线为分界,将其腹部分为左右两个区域,从怀孕第三个月开始在左腹部涂抹5号乳液,右腹部涂抹9号乳液,每日早晚各一次,直至分娩后一个月,观察其腹部妊娠纹状况,结果见表12。
表12 预防妊娠纹功效测试结果
由上述结果可见,体型正常及轻度肥胖的的初产妇,两侧均无妊娠纹出现。对于体型正常的经产妇,两侧妊娠纹也无加重状况。本发明的组合在预防妊娠纹功效上的效果和对比例1相当。
5. 修复妊娠纹功效测试
分别使用实施例3、对比例1和对比例2中的 4-13号乳液。每个样品招募30名志愿者,志愿者均为产后有明显妊娠纹的患者。以受试者腹部中线为分界,将其腹部分为左右两个区域,在每个区域选取纹路、颜色类似的一处妊娠纹,随机选取其中一侧作为给药部位。选定部位用温水清洗干净后,早晚各涂抹一次。15天为一个疗程,若连续使用30天妊娠纹无变化,则判为无效,停止治疗;有效病例连续用药3个月,评定试验结果。功效评价标准如下:显效:妊娠纹变淡且范围缩小60%(含)以上;有效:妊娠纹变淡且范围缩小30%(含)以上;无效:妊娠纹无变淡且范围不缩小。总有效率=(显效例数+有效例数)/总例数×100%。结果见下表13。
表13 修复妊娠纹功效测试结果
乳液13的总有效率为6.7%,乳液10-12的总有效率分别为70.0%、73.3%、73.3%,乳液4、乳液5、乳液6、乳液8的总有效率均为90%,乳液7的总有效率为80%,说明当甘露糖醛酯硅烷醇含量低于0.01%、乙酰壳糖胺含量低于0.01%、依克多因含量低于0.01%时效果不好,当甘露糖醛酯硅烷醇含量大于1.0%、乙酰壳糖胺含量大于0.5%、依克多因含量大于0.5%,效果没有显著增加。因此,甘露糖醛酯硅烷醇、乙酰壳糖胺、依克多因的含量分别选为0.01%-1.0%、0.01%-0.5%、0.01%-0.5%。从9号乳液和4-6号乳液的结果可以看出,本发明的组合物修复妊娠纹的效果和对比例1乳液的效果相当。
由以上结果可以看出本发明的组合物预防和治疗妊娠纹,促进胶原蛋白生成的效果和对比例1相当,在对皮肤的保湿、弹性、促进人皮肤成纤维细胞增殖效果上都略优于对比例1。和对比例1相比我们的组合物成分简单、用量少,就能达到很好的治疗效果。综上,本发明的组合物用量少效果明显,且对人体安全、无毒副作用。同时,本发明的组合物成分类型简单、易于制备,易与其他成分混配到化妆品中。
Claims (10)
1.一种预防和治疗妊娠纹的组合物,其特征在于,包括以下原料:甘露糖醛酯硅烷醇和透皮成分;所述透皮成分为乙酰壳糖胺和依克多因。
2.根据权利要求1所述的组合物,其特征在于,所述甘露糖醛酯硅烷醇与透皮成分的质量比为(4-40):(2-51);优选为4:3。
3.根据权利要求1所述的组合物,其特征在于,所述乙酰壳糖胺用量和依克多因用量的质量比为(3-5):(1-3);优选为4:2。
4.根据权利要求1所述的组合物,其特征在于,所述组合物包括以下重量百分含量的原料:甘露糖醛酯硅烷醇0.01%-1.0%、乙酰壳糖胺0.01%-0.5%、依克多因0.01%-0.5%。
5.根据权利要求1所述的组合物,其特征在于,所述组合物还包括其他预防和治疗妊娠纹的有效成分;所述有效成分选自植物提取物、维生素及其衍生物、蛋白质、肽类或氨基酸中的至少一种。
6.根据权利要求1所述的组合物,其特征在于,所述组合物还包括辅料;所述辅料选自保湿剂、防腐剂、酸碱调节剂、表面活性剂、黏度调节剂、香料和色素中的至少一种。
7.根据权利要求6所述的组合物,其特征在于,所述保湿剂选自但不限于丙三醇、山梨醇、甜菜碱、尿囊素、β-葡聚糖和聚谷氨酸钠中的一种或多种;
所述防腐剂选自但不限于戊二醇、丁二醇、苯氧乙醇、三氯叔丁醇、对羟基苯乙酮、季铵盐类、双胍类中的一种或多种;
所述酸碱调节剂选自但不限于柠檬酸、氢氧化钠、三乙醇胺和氨甲基丙醇中的一种或多种;
所述表面活性剂选自但不限于AES铵盐、K12铵盐、月桂醇醚硫酸铵、月桂醇硫酸钠、椰油酰胺丙基甜菜碱中的一种或多种;
所述的黏度调节剂选自但不限于氯化钠、氯化铵、椰油酰胺甜菜碱类、汉生胶、丙烯酸酯类中的一种或多种。
8.根据权利要求6所述的组合物,其特征在于,所述辅料包含保湿剂。
9.一种含有如权利要求1-8任一所述预防和治疗妊娠纹组合物的化妆品。
10.根据权利要求9所述的化妆品,其特征在于,种类为水、乳、霜、精华、凝胶或腹膜。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911408422.1A CN110974716B (zh) | 2019-12-31 | 2019-12-31 | 一种预防和治疗妊娠纹的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911408422.1A CN110974716B (zh) | 2019-12-31 | 2019-12-31 | 一种预防和治疗妊娠纹的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110974716A true CN110974716A (zh) | 2020-04-10 |
CN110974716B CN110974716B (zh) | 2023-02-03 |
Family
ID=70079554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911408422.1A Active CN110974716B (zh) | 2019-12-31 | 2019-12-31 | 一种预防和治疗妊娠纹的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110974716B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3126876A1 (fr) * | 2021-09-15 | 2023-03-17 | Lsi Silderma Ltd | Composition pour prévenir et/ou traiter les vergetures blanches |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1306816A (zh) * | 2000-02-03 | 2001-08-08 | 上海家化联合股份有限公司 | 一种皮肤抗皱组合物 |
WO2008090489A2 (en) * | 2007-01-23 | 2008-07-31 | L'oreal | Cosmetic skincare use of iron gluconate combinations |
CN102210869A (zh) * | 2011-04-29 | 2011-10-12 | 山东弘立医学动物实验研究有限公司 | 四氢嘧啶及其衍生物在制备透皮吸收促进剂中的应用 |
CN104997711A (zh) * | 2015-07-20 | 2015-10-28 | 陈巨根 | 一种祛疤除纹精油 |
CN108653060A (zh) * | 2018-07-29 | 2018-10-16 | 佛山市芊茹化妆品有限公司 | 一种祛孕纹护肤霜 |
CN109010180A (zh) * | 2018-09-25 | 2018-12-18 | 上海紫晨实业有限公司 | 一种孕妇用祛妊抚纹祛疤膏 |
CN109363992A (zh) * | 2018-11-28 | 2019-02-22 | 广州贝玛生物科技有限公司 | 一种孕妇妊娠纹防护及产后修复舒缓精华乳及其制备方法 |
CN109431838A (zh) * | 2018-11-02 | 2019-03-08 | 蝶柔化妆品(浙江)有限公司 | 一种无乳化剂精华及其制备方法 |
-
2019
- 2019-12-31 CN CN201911408422.1A patent/CN110974716B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1306816A (zh) * | 2000-02-03 | 2001-08-08 | 上海家化联合股份有限公司 | 一种皮肤抗皱组合物 |
WO2008090489A2 (en) * | 2007-01-23 | 2008-07-31 | L'oreal | Cosmetic skincare use of iron gluconate combinations |
CN102210869A (zh) * | 2011-04-29 | 2011-10-12 | 山东弘立医学动物实验研究有限公司 | 四氢嘧啶及其衍生物在制备透皮吸收促进剂中的应用 |
CN104997711A (zh) * | 2015-07-20 | 2015-10-28 | 陈巨根 | 一种祛疤除纹精油 |
CN108653060A (zh) * | 2018-07-29 | 2018-10-16 | 佛山市芊茹化妆品有限公司 | 一种祛孕纹护肤霜 |
CN109010180A (zh) * | 2018-09-25 | 2018-12-18 | 上海紫晨实业有限公司 | 一种孕妇用祛妊抚纹祛疤膏 |
CN109431838A (zh) * | 2018-11-02 | 2019-03-08 | 蝶柔化妆品(浙江)有限公司 | 一种无乳化剂精华及其制备方法 |
CN109363992A (zh) * | 2018-11-28 | 2019-02-22 | 广州贝玛生物科技有限公司 | 一种孕妇妊娠纹防护及产后修复舒缓精华乳及其制备方法 |
Non-Patent Citations (1)
Title |
---|
刘瑞雪等: "《高分子材料》", 30 April 2018 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3126876A1 (fr) * | 2021-09-15 | 2023-03-17 | Lsi Silderma Ltd | Composition pour prévenir et/ou traiter les vergetures blanches |
EP4151202A1 (fr) | 2021-09-15 | 2023-03-22 | LSI Silderma Ltd | Composition pour prévenir et/ou traiter les vergetures blanches |
Also Published As
Publication number | Publication date |
---|---|
CN110974716B (zh) | 2023-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020024703A1 (zh) | 一种水溶性富勒烯外用组合物 | |
CN107308020B (zh) | 一种稳定的多肽组合物及其应用 | |
CN108379110B (zh) | 护肤组合物、护肤膏霜及其制备方法 | |
CN110013447B (zh) | 一种祛除妊娠纹的膏霜及其制备方法 | |
CN108434064A (zh) | 兼具皮肤抗炎袪痘和修复功能的护肤品 | |
CN112137951A (zh) | 一种强韧发丝修复头皮屏障的无硅油透明氨基酸洗发水及其制备方法 | |
CN112022895B (zh) | 一种用于皮肤屏障修复的组合物及其制备方法 | |
CN114246817A (zh) | 一种祛皱组合物及其制备方法和应用 | |
CN114948788A (zh) | 一种舒缓修护三重蛋白组合物及其应用 | |
HU230039B1 (hu) | Hipoallergén és nem irritáló bőrápoló készítmények | |
WO2019245229A1 (ko) | 7-데하이드로콜레스테롤, 콜레스테롤 및 스테아린산이 히알루론산-세라마이드 엔피 복합체의 내상에 봉입된 나노에멀젼을 함유하는 화장료 조성물 | |
JP4288306B2 (ja) | ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有化粧料 | |
CN110974716B (zh) | 一种预防和治疗妊娠纹的组合物 | |
CN112370393B (zh) | 一种洗发慕斯组合物及其制备方法与应用 | |
CN108354891B (zh) | 一种舒缓乳霜及其制备方法 | |
JPH06305932A (ja) | 皮膚外用剤 | |
CN110302136A (zh) | 美白护肤组合物 | |
JPH0995432A (ja) | 皮膚外用剤 | |
CN115737451A (zh) | 一种α-凝胶组合物、化妆品及其制备方法 | |
CN115887336A (zh) | 用于皮肤的祛红组合物和化妆品 | |
KR101979658B1 (ko) | 순지트를 이용한 탈모 방지 및 발모 촉진용 화장료 조성물 제조 방법 | |
CN113425642B (zh) | 一种眼部护理组合物 | |
JP5137786B2 (ja) | ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有クレンジング化粧料 | |
JP5313524B2 (ja) | 抗炎症剤及び抗炎症用皮膚外用剤 | |
CN115737460A (zh) | 一种天然保湿抗氧化型涂抹式面膜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230629 Address after: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee after: BLOOMAGE BIOTECH Co.,Ltd. Patentee after: Huaxi Biotechnology (Tianjin) Co.,Ltd. Address before: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee before: BLOOMAGE BIOTECH Co.,Ltd. Patentee before: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. |
|
TR01 | Transfer of patent right |